Beranda › Tekanan Darah Tinggi › Arizona
Uji klinis Tekanan Darah Tinggi di Arizona
12 studi untuk Tekanan Darah Tinggi mencari peserta di lokasi di Arizona.
Kota di Arizona
Teks studi resmi (Bahasa Inggris)
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
- Retension Clinical Site, Tucson
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07142356A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
- Banner - University Medical Center Tucson, Tucson
Menerima peserta
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07214376A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Pima Heart, Tucson
- Eclipse Clinical Research, Tucson
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07783802EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Arizona Clinical Trials - Chandler, Chandler
- Elite Clinical Studies, Phoenix
- Clinical Research Institute of Arizona, LLC, Sun City West
- dan 3 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07064473A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Care Access - 801 South Power Road, Mesa, Mesa
- Absolute Clinical Research, Phoenix
- Synexus Clinical Research US, Inc./Orange Grove Family Practice, Tucson
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07794579A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
- Research Site, Surprise
- Research Site, Tucson
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06742723THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
- HonorHealth, Scottsdale
Menerima peserta
Usia 22 hingga 75 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06559891Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- Clinical Trial Site, Chandler
- Clinical Trial Site, Gilbert
- Clinical Trial Site, Mesa
- dan 8 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT07181109Arizona CEAL: Linking Social Care With Healthcare Systems to Address SDOH
- Banner University Medical Center South, Tucson
- UAHS Center for Sleep, Circadian, & Neuroscience Research Department of Medicine, University of Arizona, Tucson
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07799961Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
- Vanda Investigative Site, Phoenix
- Vanda Investigative Site, Tempe
- Vanda Investigative Site, Tucson
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 27 Feb 2026 · NCT07090161bpMedManage: Digital Technology to Support Adherence to Hypertension Medications
- University of Arizona, Tucson
Menerima peserta
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 15 Okt 2025 · NCT06307574CardioCare Quest: A Co-created Game for Improving Hypertension Treatment Compliance in Arizona
- School of Informatics Computing and Cyber Systems, Flagstaff
- Northern Arizona University, Flagstaff
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Jun 2025 · NCT06487637Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.